Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Jeffrey A. Meyerhardt, MD
|
|
Give Review
Jeffrey Meyerhardt practices Oncology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He received awards:"Regional Top Doctor" and "Whos Who in Medicine and Healthcare". Jeffrey Meyerhardt has written publications. He has 98 publications published with PubMed. The lastest paper is: 'Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer.' Jeffrey A. Meyerhardt accepts Medicare.
Publications
- Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer.
- Diet and Lifestyle in Survivors of Colorectal Cancer.
- Practical clinical interventions for diet, physical activity, and weight control in Cancer survivors.
- Aspirin and COX-2 inhibitor use in patients with stage III colon Cancer.
- CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal Cancer.
- Prognostic Significance and Molecular Features of Signet-Ring Cell and Mucinous Components in ColoRectal Carcinoma.
- Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis.
- SMO Expression in Colorectal Cancer: Associations with Clinical, Pathological, and Molecular Features.
- Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal Cancer.
- Discovery of colorectal Cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma.
- Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer.
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial.
- Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial.
- Perioperative chemotherapy for colorectal Cancer liver metastases.
- Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Gu...
- Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance.
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication.
- Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database.
- A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine Tumors.
- A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic Neuroendocrine tumor.
- Physical Activity, Tumor PTGS2 Expression, and Survival in Patients with Colorectal Cancer.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study.
- Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients: Colon vs. Rectal Cancer.
- The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) Initiative: Rationale and Design.
- The impact of glycemic levels in patients with colon Cancer.
- Feasibility of computer-based self-administered Cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.
- Prospective Study of Family History and Colorectal Cancer Risk by Tumor LINE-1 Methylation Level.
- Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405.
- Molecular pathological epidemiology of epigenetics: emerging integrative science to Analyze environment, host, and disease.
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers.
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors.
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer.
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer.
- Prognostic Significance and Molecular Associations of Tumor Growth Pattern in Colorectal Cancer.
- Energy in and Energy out: What Matters for Survivors of Colorectal Cancer?
- Tumor TP53 expression status, body mass index, and prognosis in colorectal Cancer.
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal Cancers.
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.
- Beyond standard adjuvant therapy for colon Cancer: role of nonstandard interventions.
- Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer.
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
- Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal Cancer.
- Reported behavior of eating anything at anytime and risk of colorectal Cancer in women.
- Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741.
- Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal Cancers.
- Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal Cancers: Cohort study and literature review.
- TGFBR2 and BAX Mononucleotide Tract Mutations, Microsatellite Instability, and Prognosis in 1072 Colorectal Cancers.
- Dietary insulin load, dietary insulin index, and colorectal Cancer.
- Adjuvant Therapy for Stage II and III Colon Cancer.
- A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid Tumors.
- Multivitamin use is not associated with Cancer recurrence or survival in patients with stage III colon Cancer: findings from CALGB 89803.
- Host factors and Cancer outcome.
- Energetics in colorectal and prostate Cancer.
- HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal Cancers.
- Impact of smoking on patients with stage III colon Cancer: results from Cancer and Leukemia Group B 89803.
- Negative lymph node count is associated with survival of colorectal Cancer patients, independent of tumoral molecular alterations and lymphocytic reaction.
- New developments in the adjuvant therapy of stage II colon Cancer. Risk assessments in the older patient.
- Physical activity and male colorectal Cancer survival.
- Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?
- A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal Cancers.
- Lymphocytic reaction to colorectal Cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator ph...
- Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal Cancer.
- Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal Cancers.
- Interaction of molecular markers and physical activity on mortality in patients with colon Cancer.
- p21 expression in colon Cancer and modifying effects of patient age and body mass index on prognosis.
- Relationship of CDX2 loss with molecular features and prognosis in colorectal Cancer.
- A cohort study of cyclin D1 expression and prognosis in 602 colon Cancer cases.
- A cohort study of p27 localization in colon Cancer, body mass index, and patient survival.
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric Cancer.
- Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal Cancer.
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic Cancer.
- O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine Tumors.
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon Cancer.
- Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal Cancer: results from intergroup trial N9741.
- Cohort study of fatty acid synthase expression and patient survival in colon Cancer.
- DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic Neuroendocrine tumor.
- Prediagnostic plasma folate and the risk of death in patients with colorectal Cancer.
- Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal Cancer.
- Association of family history with Cancer recurrence and survival among patients with stage III colon Cancer.
- Family history and survival after colorectal Cancer diagnosis.
- CpG island methylator phenotype-low (CIMP-low) colorectal Cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at indivi...
- Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder Cancer.
- Aspirin dose and duration of use and risk of colorectal Cancer in men.
- Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic Cancer.
- Association of dietary patterns with Cancer recurrence and survival in patients with stage III colon Cancer.
- Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
- Adjuvant and neoadjuvant approaches in gastric Cancer.
- Adjuvant treatment of colorectal Cancer.
- Impact of hospital volume on recurrence and survival after surgery for gastric Cancer.
- Hormone replacement therapy and survival after colorectal Cancer diagnosis.
- Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal Cancer.
- Impact of physical activity on Cancer recurrence and survival in patients with stage III colon Cancer: findings from CALGB 89803.
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine Tumors.
- Physical activity and survival after colorectal Cancer diagnosis.
- Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal Cancer.
Schools
Yale University School Of Medicine
Beth Israel Deaconess Mc
Dana Farber Cancer Center Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Harvard Pilgrim Health Care PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Neighborhood Health Plan
- Simplifi
- Tufts Health Plans
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- Whos Who in Medicine and Healthcare
Education
-
Brigham and Women's Hospital -
Beth Israel Deaconess Medical Center -
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital -
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1548238710 | |
| NPPES Provider LastName | MEYERHARDT | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 021156013 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 172.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548238710 |
| Last Name Of The Provider | MEYERHARDT |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Inga T. Lennes, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Ligibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Supriya K. Saha, MD |
|
|
Dr. Mandar D. Muzumdar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yeowon A. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole G. Chau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kerry L. Massman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip C. Amrein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian M. Wolpin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eyal C. Attar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lecia V. Sequist, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven E. Come, MD
This Doctor is OpenDoctor Recommended.
|